TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04503499

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manuel Therapy
Description: The manual therapy protocol will consist of 45-60 minutes and the following techniques;~* suboccipital decompression~* cervical mobilization (in the posterior-anterior direction)~* sternocleidomastoid release~* scalene release~* trapezoidal release~* scalene release~* pectoralis tractus~* sternoclavicular joint mobilization~* sternum mobilization~* parasternal circumference intercostal and paravertebral release~* diaphragm release~* rib reasing~* scapulothoracic joint mobilization~* thoracic vertebra mobilization~Myofascial release techniques will be applied for 3-5 minutes each.~Mobilization techniques were applied in each joint for 30 seconds and 5 times.
Study: NCT04417036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1097761 Active Dose 1
Description: Participants will receive a lower dose ADM by inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1097761 Active Dose 1
Description: Participants will receive a lower dose ADM by inhalation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to BAY1097761
Description: Participants will receive Placebo to BAY1097761 by inhalation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to BAY1097761
Description: Participants will receive Placebo to BAY1097761 by inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1097761 Active Dose 2
Description: Participants will receive a higher dose ADM by inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1097761 Active Dose 2
Description: Participants will receive a higher dose ADM by inhalation
Study: NCT03332823

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SME Ambassadors training & program
Description: * Two train-the-ambassador workshops: to train the ambassadors on positive thinking and understanding of adult mental health problem (in particular the mixed anxiety and depressive disorder) and mental well-being.~* The trained SME ambassadors will provide voluntary services and promote mental well-being messages to vulnerable groups, such as ex-mental illness people, new arrivals, etc.
Study: NCT01517893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated
Study: NCT03622489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: mentioned above

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: mentioned above
Study: NCT01517893

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated
Study: NCT00871520

Intervention type: OTHER
Intervention: no specific interventions
Description: There are no specific interventions in this observational study
Study: NCT04004637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD7 CAR-T cells infusion
Description: Biological: CD7 CAR-T cells infusion. Pretreatment: patients enrolled in this study will receive cyclophosphamide or fludarabine plus cyclophosphamide. CD7 CAR-T cells infusion are allowed within 2 weeks after treatment.~CD7 CAR-T cells infusion: 30-60 minutes before infusion, H1 anti-histamine agents are applied (acetaminophen 30mg,po.; promethazine 25mg,i.v. ; diphenhydramine 0.5-1mg/kg, no more than 50mg.). Non-physiological doses of corticosteroids are not applied for patients during treatment or recovery unless a life-threatening emergency occurs. CD7 CAR-T cells are infused into patients for one or two times, the number of infused CD7 CAR-T cells are 0.5-5×10\^6/kg.
Study: NCT01599403

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Paravertebral Block
Description: The paravertebral block consists of injection of local anesthetics into the area next to the spinal column and results in regional pain control. This technique of this block may be performed on multiple levels if there are extensive rib fractures and may be performed on both sides of the rib cage depending on injury.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intercostal Nerve Block
Description: The intercostal nerve block will consist of placing a catheter which delivers pain medication into the area between the ribs. This technique of this block may be performed on multiple levels if there are extensive rib fractures and may be performed on both sides of the rib cage depending on injury.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epidural Block
Description: The epidural block consists of continuous infusion of local anesthetics into the epidural catheter placed into the epidural space (next to the spinal column) and results in regional pain control. This technique of this block may be performed at the appropriate level so the pain of rib fracture may be better controlled.
Study: NCT01560780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: one 10 mg tablet by mouth daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo similar in appearance to prasugrel
Study: NCT02055820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax 200 to 800 milligrams (mg) tablets will be administered orally once daily (QD) on Days 4-10 of Cycle 1 and Days 1-10 of Cycles 2-8 during Phase I and MTD will be administered according to the same schedule during Phase II.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax 200 to 800 milligrams (mg) tablets will be administered orally once daily (QD) on Days 4-10 of Cycle 1 and Days 1-10 of Cycles 2-8 during Phase I and MTD will be administered according to the same schedule during Phase II.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 750 milligrams per square meter (mg/m\^2) administered intravenously (IV) on Day 1 of each 21-day cycle up to Cycle 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 750 milligrams per square meter (mg/m\^2) administered intravenously (IV) on Day 1 of each 21-day cycle up to Cycle 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab will be administered by IV infusion as an absolute dose of 1000 mg on Days 1, 8, 15 of Cycle 1 and Day 1 of Cycles 2-8 (cycle length = 21 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m\^2 dose will be administered IV on Day 1 of every 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin 50 mg/m\^2 administered IV on Day 1 of each 21-day cycle up to Cycle 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin 50 mg/m\^2 administered IV on Day 1 of each 21-day cycle up to Cycle 6.
Study: NCT03622489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: mentioned above
Study: NCT02055820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine 1.4 mg/m\^2 (maximum 2 mg) administered IV on Day 1 of each 21-day cycle up to Cycle 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine 1.4 mg/m\^2 (maximum 2 mg) administered IV on Day 1 of each 21-day cycle up to Cycle 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 100 mg per day orally on Days 1-5 of each 21-day cycle up to Cycle 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 100 mg per day orally on Days 1-5 of each 21-day cycle up to Cycle 6.
Study: NCT03853603

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Santa herba
Description: Santa herba dry extract; 400 mg/day. 2 capsules/day; 1 capsule twice daily with the main meals (lunch and dinner)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin; 400 mg/day. 2 capsules/day; 1 capsule twice daily with the main meals (lunch and dinner)
Study: NCT02107638

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OMM treatment arm
Description: OMM is a gentle hand-on manual therapy. The research team created a protocol coined PARK-OMM protocol. These techniques aim to help treat myofascial restrictions and improve joint range of motion.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Counseling
Description: Patients will be counseled on Parkinson's Disease related issues including prevention of falls, medications, diet, nutrition, exercise, tai-chi, yoga, meditation, and mental health.
Study: NCT02092012

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexketoprofen trometamol
Description: ıv 50 mg dexketoprofen trometamol after anaesthesia induction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: ıv 1 mcg/kg dexmedetomidine after anaesthesia induction
Study: NCT03363321

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06741086
Description: PF-06741086 subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06741086
Description: PF-06741086 subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06741086
Description: PF-06741086 subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06741086
Description: PF-06741086 subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06741086
Description: PF-06741086 subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06741086
Description: PF-06741086 subcutaneous injection
Study: NCT04046003

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai chi exercise
Description: 24-form Yang style Tai Chi (60 min/session, 3 sessions/week) for 8 weeks
Study: NCT03269435

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Greater occipital nerve block with bupivacaine
Description: This is a type of peripheral nerve block. 3cc of 0.5% bupivacaine will be injected adjacent to the greater occipital nerve block blaterally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide
Description: Metoclopramide 10mg IV will be administered over 15 minutes
Study: NCT03742180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal dexmedetomidine
Description: The patient will receive intranasal dexmedetomidine in a dose of 1ug.kg-1 in a volume of 1 ml was dripped into both nostrils using a 1-mL syringe, with the patients in the recumbent position plus 1ml sublingual 0.9% saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sublingual ketorolac
Description: The patient will receive sublingual ketorolac in a dose of 0.5 mg.kg-1 in a volume of 1 ml and 1 ml intranasal saline 0.9%
Study: NCT04490863

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rad-67 Pulse oximeter & DCI Mini sensor
Description: Noninvasive pulse oximeter that measures hemoglobin
Study: NCT03099187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: Pirfenidone 267 mg capsules three times in a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo capsules three times in a day.
Study: NCT00761007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibodutant
Description: Oral tablet, dose level 1 (10 mg), once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibodutant
Description: Oral tablet, dose level 2 (30 mg), once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibodutant
Description: Oral tablet, dose level 3 (60 mg), once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet matching the three dose levels of ibodutant, once daily
Study: NCT03399877

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Combining electromyography with uroflowmetry (group A)
Description: Children who assigned group A perform uroflowmetry-electromyography for the first and subsequently perform uroflowmetry-electromyography again.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Uroflowmetry(Group B)
Description: Children who assigned Group B perform uroflowmetry-electromyography for the first, and subsequently perform sole uroflowmetry.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Uroflowmetry-Combining electromyography with uroflowmetry (Group C)
Description: Children who assigned Group C firstly perform sole uroflowmetry and subsequently perform uroflowmetry-electromyography.
Study: NCT00919100

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Buzzy
Description: Buzzy is a vibrating cold pack attached with Velcro strap or tourniquet 5-10cm proximal to the site of venipuncture. The vibration is activated and the device remains in place throughout the procedure. The distraction cards are offered to the parents to show the children, with questions on the back and pictures on the front.

Intervention type: OTHER
Group type: OTHER
Intervention: vapocoolant
Description: venipuncture with vapocoolant spray offered
Study: NCT04200261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Banapenem
Description: 2000 mg group is performed firstly. After completion of observation and confirming that the drug can be safely tolerated, study on 3000 mg group is then performed

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sodium chloride
Description: sodium chloride
Study: NCT01867281

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin
Study: NCT04523311

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis.
Description: Online, group-based, single session hypnosis workshop followed by 2 weeks of self hypnosis.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Participants will be asked to continue with whatever interventions they are already receiving/employing to manage their migraine and tension-type headaches.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Participants will be asked to continue with whatever interventions they are already receiving/employing to manage their migraine and tension-type headaches.
Study: NCT00662402

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extensive Consultations
Description: receives 15 free hours of multidisciplinary consultations towards the preparation of their career development grant.
Study: NCT00271596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20mg daily citalopram
Description: a selective serotonin reuptake inhibitor (SSRI) treatment administered over 16 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: a daily matching placebo administered over 16 weeks
Study: NCT01161264

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2010/2011
Description: Single 0.5 mL dose administered into the deltoid muscle of (preferably) the non-dominant arm on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2010/2011
Description: Single 0.5 mL dose administered into the deltoid muscle of (preferably) the non-dominant arm on Day 1.
Study: NCT01339806

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Rehab
Description: APT-III, Other standard individual and group interventions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Rehab
Description: APT-III, Other standard individual and group interventions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brainworks
Description: POSIT

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Informational Handout/Provider Visits
Description: Provider based visits every three weeks and informational handout given to patient in regulation with current standard of care procedures.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Informational Handout/Provider Visits
Description: Provider based visits every three weeks and informational handout given to patient in regulation with current standard of care procedures.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Informational Handout/Provider Visits
Description: Provider based visits every three weeks and informational handout given to patient in regulation with current standard of care procedures.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Informational Handout/Provider Visits
Description: Provider based visits every three weeks and informational handout given to patient in regulation with current standard of care procedures.
Study: NCT01155804

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: preparation of the delivery
Description: Pregnant nulliparous women allocated to the non-interventional group will follow the routine pre-natal care. The participants of the study group will receive routine attention at the pre-natal care service and will also participate in the program of physical and educational after each routine pre-natal consultation. These activities will be organize as follow: 30 minutes of physical exercise for the prevention of pain and discomfort that may occur during pregnancy, preparation of the perineal muscles for delivery and prevention of urinary incontinence, 15 minutes for relaxation and 30 minutes for group discussion to respond to doubts that women may have and issues such as: change in posture during pregnancy and prevention of pain and discomfort; role of the perineal muscles during pregnancy, delivery and puerperium, physiology of delivery, non-pharmacological way for pain relief and breathing control during contractions of labor and delivery.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: preparation of the delivery
Description: Pregnant nulliparous women allocated to the non-interventional group will follow the routine pre-natal care. The participants of the study group will receive routine attention at the pre-natal care service and will also participate in the program of physical and educational after each routine pre-natal consultation. These activities will be organize as follow: 30 minutes of physical exercise for the prevention of pain and discomfort that may occur during pregnancy, preparation of the perineal muscles for delivery and prevention of urinary incontinence, 15 minutes for relaxation and 30 minutes for group discussion to respond to doubts that women may have and issues such as: change in posture during pregnancy and prevention of pain and discomfort; role of the perineal muscles during pregnancy, delivery and puerperium, physiology of delivery, non-pharmacological way for pain relief and breathing control during contractions of labor and delivery.
Study: NCT02878954

Intervention type: OTHER
Group type: OTHER
Intervention: No intervention (Observational study)
Description: 160 patients will be recruited to:~* Fill in questionnaires related to demographic characteristics, severity of disease and physical activity.~* Perform a six-minute walk test Comparison between men and women will be performed.

Intervention type: OTHER
Group type: OTHER
Intervention: Control session
Description: Out of the 160 participants of the observational study, at least 40 (20 men and 20 women) will be recruited.~In the control session participants will be seated in resting position for 15 minutes.

Intervention type: OTHER
Group type: OTHER
Intervention: Control session
Description: Out of the 160 participants of the observational study, at least 40 (20 men and 20 women) will be recruited.~In the control session participants will be seated in resting position for 15 minutes.

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise session
Description: 40 patients will perform a single maximal exercise test on a treadmill. Speed will be maintained at 3.2 km/h and the grade will be increased with 2% every 2 min following Gardner's protocol.

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise session
Description: 40 patients will perform a single maximal exercise test on a treadmill. Speed will be maintained at 3.2 km/h and the grade will be increased with 2% every 2 min following Gardner's protocol.
Study: NCT01432873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral selenium
Description: Drug: selenium tablet Oral selenium 1 Tab bid from day -6/-7 until discharge

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral placebo
Description: Drug: Placebo Oral placebo 1 Tab bid from day -6/-7 until discharge
Study: NCT00912249

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Horticulture Therapy
Description: We will design courses of Horticultural therapy to provide to the Patients in Day Care Unit
Study: NCT04539561

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PiQo4 Laser System
Description: PiQo4 Laser System for treatment of hand pigmentation
Study: NCT03622489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramal
Description: mentioned above

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramal
Description: mentioned above
Study: NCT01500278

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate (MTX)
Description: * Active substance: Methotrexate~* Pharmaceutical form: oral tablet~* Concentration: 15-25 mg/week~* Route of Administration: MTX orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate (MTX)
Description: * Active substance: Methotrexate~* Pharmaceutical form: oral tablet~* Concentration: 15-25 mg/week~* Route of Administration: MTX orally
Study: NCT04526561

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Latissimus dorsi flap
Description: Breast reconstruction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracodorsal artery perforator flap to breast
Description: Breast reconstruction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deep inferior epigastric perforator flap
Description: Breast reconstruction
Study: NCT04643912

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Vibration Device
Description: Device which causes the bone to vibrate and records the spectrum of that vibration
Study: NCT02907385

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LifeSeal™ Kit
Description: LifeSeal™ Kit is applied as an additional protective layer over a stapled anastomosis
Study: NCT03971201

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hepatic resection
Description: removal of portion of liver containing cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: sorafenib either as adjuvant therapy after resection or as only treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: sorafenib either as adjuvant therapy after resection or as only treatment